Apremilast is a medicine used to treat psoriasis, psoriatic arthritis and mouth sores caused by Behcet's disease. It works by calming down overactive inflammation inside the body's cells. It's taken as a pill by mouth.
Every report comes from a Lived member, sent anonymously.
Have you tried Otezla (Apremilast) for Psoriasis?
Apremilast, sold as Otezla and the once-daily Otezla XR, is a prescription tablet that calms inflammation in three conditions. It treats active psoriatic arthritis, a form of arthritis that causes painful, swollen joints in some people with psoriasis. It treats plaque psoriasis, where raised, scaly patches form on the skin, in adults who need more than creams alone and could be considered for light therapy or whole-body treatment. It also treats the painful mouth ulcers of Behçet's disease, a rare inflammatory disorder of the blood vessels, in adults. Children 6 and older can use it for psoriatic arthritis or moderate to severe plaque psoriasis if they weigh at least 20 kg (about 44 pounds). Otezla XR is limited to people weighing at least 50 kg (about 110 pounds). Because it is a pill rather than an injection, apremilast is often considered by people who want to avoid injected biologic medicines or who have not done well enough with skin treatments. Choosing between them usually means weighing the convenience of a pill and its side effects against how much improvement a person needs.
Inside immune and skin cells, an enzyme called phosphodiesterase 4 (PDE4) breaks down cyclic AMP (cAMP), a messenger molecule that helps keep inflammatory signaling in check. Apremilast blocks PDE4, so cyclic AMP builds up inside the cell. In studies, this lowered levels of several inflammatory signaling proteins that drive psoriasis, both in the blood and in the skin. The result is a broad dampening of overactive inflammation rather than a shutdown of one specific target, which is part of why its effect is real but usually moderate. Exactly how this translates into clearer skin, calmer joints and fewer mouth ulcers is not fully understood.
Apremilast is started gradually. For the first five days, a starter pack steps the dose up from a small morning tablet to the full dose, which helps reduce nausea and diarrhea. This starter pack uses regular Otezla tablets even when the plan is to continue on Otezla XR. After that, most adults take Otezla twice a day or one Otezla XR tablet once a day. Children's doses depend on body weight. Tablets can be taken with or without food and should be swallowed whole, not crushed, split or chewed. People with severe kidney disease take a lower, once-daily dose of regular Otezla, and Otezla XR is not recommended for them. People taking Otezla XR may sometimes see an empty tablet shell in their stool; the medicine has already been absorbed by then.
Diarrhea, nausea and headache are the most common side effects, along with colds and other upper respiratory infections. They usually appear in the first two weeks and often fade with continued use, which is why the dose is increased gradually at the start. Occasionally diarrhea, nausea or vomiting becomes severe, and some people have needed hospital care, mostly in the first few weeks. Contact the prescriber promptly if this happens. The risk of dehydration or dizziness from low blood pressure is higher in people 65 and older and in those taking medicines that lower fluid levels or blood pressure. Lowering or pausing the dose usually brings quick relief. Weight loss is fairly common. In psoriasis trials, about 1 in 8 adults lost 5 to 10 percent of their body weight, compared with 1 in 20 on a placebo. Weight is checked during treatment, and children's height and weight are tracked to make sure they are growing as expected. Unexplained or significant weight loss should be reported. Serious allergic reactions are rare. Swelling of the face, lips, tongue or throat, or trouble breathing, needs emergency care right away (call 911).
Apremilast is linked to a higher rate of depression than placebo. Before starting, tell the prescriber about any history of depression or suicidal thoughts, since the benefits and risks need careful weighing. During treatment, patients and the people close to them should watch for new or worsening depression, suicidal thoughts or other mood changes, and contact the prescriber promptly if they appear. Some medicines speed up the liver's breakdown of apremilast enough that it may stop working. These include rifampin, an antibiotic used for tuberculosis, and the seizure medicines carbamazepine, phenytoin and phenobarbital. Using them together is not recommended. Do not take apremilast with a known allergy to it. Human pregnancy data are limited, and animal studies showed a higher rate of pregnancy loss at doses above those used in people. Anyone pregnant, planning pregnancy or breastfeeding should discuss whether to continue, since it is not known whether apremilast passes into breast milk.
Some people notice less itching within the first couple of weeks, but changes in skin, joints or mouth ulcers build over several months. Trials judged results at about 12 weeks for Behçet's mouth ulcers and 16 weeks for psoriasis and psoriatic arthritis. Response varies. In the main adult psoriasis trials, about 3 in 10 people reached a 75 percent improvement in their psoriasis score by 16 weeks, compared with about 1 in 20 on placebo. In psoriatic arthritis, roughly a third to 4 in 10 had at least a 20 percent improvement in joint symptoms, compared with fewer than 1 in 5 on placebo; larger improvements were less common. In Behçet's disease, about half were free of mouth ulcers at 12 weeks, compared with about 1 in 5 on placebo. Apremilast does not usually need routine blood tests, which makes follow-up simpler than with some other whole-body treatments. Visits focus on how well it is working, digestive side effects, weight and mood. Benefits fade when it is stopped: in one trial, people who switched to placebo typically lost their improvement within about five weeks. If the response is not enough, a different or added treatment may be considered.
Last reviewed • Oct 2026
Educational content, not medical advice.
Share your experience taking Otezla (Apremilast), what you've noticed, or ask the community a question.